Exhibit 99.1

 January 2023  JP Morgan Presentation  
 
 Forward Looking Statements and Non-GAAP Financial Information   2  This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Actual results may differ materially from those expressed in, or implied by, these statements as a result of various factors, including, but not limited to, (i) new laws and regulations, (ii) our ability to obtain, protect and maintain market exclusivity rights and enforce patents and other intellectual property rights, (iii) our ability to achieve expected clinical, regulatory and contractual milestones on expected timelines or at all, (iv) difficulties or delays in the development and commercialization of new products, (v) difficulties or delays in our clinical trials and the manufacturing, distribution and sale of our products, (vi) adverse outcomes in legal or regulatory proceedings, (vii) risks relating to acquisitions, divestitures, alliances, joint ventures and other portfolio actions and (viii) political and financial instability, including changes in general economic conditions. These and other important factors are discussed in the Company’s most recent annual report on Form 10-K and reports on Forms 10-Q and 8-K. These documents are available on the U.S. Securities and Exchange Commission’s website, on the Company’s website or from Bristol-Myers Squibb Investor Relations. No forward-looking statements can be guaranteed.  In addition, any forward-looking statements and clinical data included herein are presented only as of the date hereof. Except as otherwise required by applicable law, the Company undertakes no obligation to publicly update any of the provided information, whether as a result of new information, future events, changed circumstances or otherwise.  This presentation includes certain non-generally accepted accounting principles (“GAAP”) financial measures that we use to describe the Company’s performance.  The non-GAAP financial measures are provided as supplemental information and are presented because management has evaluated the Company’s financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the Company’s baseline performance, supplement or enhance management’s, analysts’ and investors’ overall understanding of the Company’s underlying financial performance and trends and facilitate comparisons among current, past and future periods. In addition, non-GAAP operating margin, which is gross profit less marketing, selling and administrative expense and research and development expense excluding certain specified items as a percentage of revenues, is relevant and useful for investors because it allows investors to view performance in a manner similar to the method used by our management and makes it easier for investors, analysts and peers to compare our operating performance to other companies in our industry.  This presentation also provides certain revenues and expenses excluding the impact of foreign exchange (“Ex-FX”). We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Ex-FX financial measures are not accounted for according to GAAP because they remove the effects of currency movements from GAAP results.   The non-GAAP information presented herein provides investors with additional useful information but should not be considered in isolation or as substitutes for the related GAAP measures. Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable financial measure are available on our website at www.bms.com/investors.   Also note that a reconciliation of forward-looking non-GAAP operating margin is not provided because a comparable GAAP measure is not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of the unwind of inventory purchase price adjustments, accelerated depreciation and impairment of property, plant and equipment and intangible assets, and stock compensation resulting from acquisition-related equity awards, or currency exchange rates. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. 
 
 Our Strategic Foundation  3  A differentiated biopharma company focused on innovative medicines for patients with cancer and other serious diseases  BEST OF BIOTECH  BEST OF PHARMA  Leading scientific innovation  Collaborating at center of the biotech ecosystem  Leveraging global scale and agility  Driven by the best people 
 
 Cardiovascular  Portfolio Strength and Breadth Across Key Franchises  4  NewProductPortfolio  Robust early-stage pipeline with 50+ assets in development  iberdomide2  milvexian3  cendakimab2  InlineBrands  Mid-to-  late-stage   Pipeline  mezigdomide2  alnuctamab BCMA TCE1  repotrectinib2  LPA1 antagonist3  AR-LDD1  CC-992821  1 In Ph 1 or Phase 1/2 development, 2 Phase 3/pivotal study, 3 POC established & planned registrational trials   farletuzumab ecteribulin1  Hematology  Immunology/Fibrosis  Oncology 
 
 MYOK, TPTX  15+  Delivered Significant Financial & Portfolio Milestones Through Strong Execution  5  Sales growth  High single-digit  Non-GAAP EPS growth  Mid-20s  Cost synergies  $3B+  $40B+  Significant Operating   Cash Flow2  3 First-in-Class Assets Approved in 2022  BD execution  Added new indications   across portfolio  9  New products delivered  ~3 Year Financial Achievements1  ~3 Year Portfolio Achievements3  Strengthens Foundation for Portfolio Renewal & Long-Term Growth  1 Financial Achievements from 2020-2022; Sales and EPS based on non-compounded growth to mid-point of 2022 guidance. Does not include impact from 4Q 2022 results  -EPS calculation excludes Acquired IPR&D impact from the MYOK acquisition in 2020; including this impact, the EPS growth rate would be in excess of 500%  2 Operating cashflow generated from 2020 to Q3 2022  3 Portfolio Achievements from 2H’19 – 2022 
 
 Strategically Positioned for Waves of Innovation  6  Additional optionality from disciplined business development  9 NMELaunches inNew Product Portfolio   6Next Wave RegistrationalStage Assets   50+Assets in Early Development  Revenue  Time  Wave 1  Wave 2  Wave 3  Illustrative 
 
 Multiple Paths for Long-Term Growth  7  2020-2025  On track to deliver   Low-to-mid single digit revenue CAGR*  $8B - 10B growth from in-line brands (primarily I-O & Eliquis)  $10B - 13B from New Product Portfolio  40%+ operating margin**  2025 Revenues  LOE Brands  2030Revenues  Additionalgrowth fromNew Product Portfolio  Next Waveof innovation: 6 registrational stage assets  Optionality from early-stage pipeline & BD  2025-2030  *At constant exchange rates on a risk-adjusted basis;   **See "Forward-Looking Statements and Non-GAAP Financial Information“ and “Bristol Myers Squibb Company Reconciliation of Certain GAAP Line Items to Certain Non-GAAP Line Items.”  NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval Financial projections may contain non promoted sales, BMS promotes only according to label 
 
 Younger & More Diversified Portfolio Through the Decade  8  Not for Product Promotional Use  New Product Portfolio = Abecma, Breyanzi, Inrebic, Onureg, Reblozyl, Zeposia, Sotyktu, Camzyos, Opdualag  Overall Portfolio – Stage in Life Cycle  ProductDiversification  Later  Earlier  NewProductPortfolio  New ProductPortfolio  Revlimid, Abraxane, Sprycel  Revlimid, Abraxane, Sprycel  Higher  Lower  2020  2025  NewProductPortfolio  Next Wave 6+ and Early Pipeline  2030   Eliquis, I-O & Other In-line Products   Eliquis,   I-O & Other In-line Products   Eliquis, I-O & Other In-line Products 
 
 Well Positioned for Portfolio Renewal & Long-Term Growth  9  1. Portfolio renewal well-underway: 9 new launches  2. Next wave of innovation: 6 registrational stage pipeline assets  3. Optionality from early-stage pipeline & BD 
 
 Strong Progress with New Product Portfolio  10  >$2B annual run-rate  10+ potential   additional indications  New Product Portfolio  Strong Momentum  $5  $1  +61%  Q3 2022 Versus Prior Year 
 
  First-in-Class Myosin Inhibitor Approved in U.S. for oHCM   11  Strong momentum into 2023  VALOR PDUFA June 16, 2023  Initiated Ph3 trial in nHCM (ODYSSEY-HCM)  $4B+ 2030 NRA sales potential  Progress Driving Adoption  1BMS Market Research  NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approvalFinancial projections may contain non promoted sales, BMS promotes only according to label  Addresses underlying disease  ~70K symptomatic oHCM patients in the US1  Most patients treated at ~500 centers  Current diagnosis1 rate: 20-25%; potential to roughly double over time  EU approval expected in 2023  REMS certified physicians  Patients in hub  Patients on commercial drug  >2000  >1100  >350  >2600  >1800  >900  As of September 30, 2022  As of December 31, 2022  Focus on driving demand & conversion to commercial dispenses  First novel treatment in oHCM  Expansion Opportunities  Camzyos  Opdualag  Sotyktu 
 
  First-in-Class Selective Allosteric TYK2 Inhibitor  12  U.S. Approval September 2022 – EU expected 2023   TRx equivalent = commercial and bridge prescriptions  NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approvalFinancial projections may contain non promoted sales, BMS promotes only according to label  Focus on building volume to secure broader access in 2024  25-30%** of new oral prescriptions in the first few months of launch  >2,000* TRx equivalent since launch  Roughly evenly split between systemic-naïve, Otezla-experienced & biologic-experienced  Strong InitialVolume  GrowingMarket Share  Broad Sourceof Business  Superior efficacy of once-daily, oral SOTYKTU vs. twice-daily Otezla in improving skin clearance for moderate-to-severe plaque psoriasis  Well-demonstrated safety and tolerability profile with no Boxed Warning  $4B+ 2030 NRA sales potential  Camzyos  Opdualag  Sotyktu  *As of December 31, 2022  **Based on brand impact through October 2022 
 
  First-in-Class LAG-3 Inhibitor, Relatlimab, as Fixed Dose Combination with Nivolumab Approved in 1L Melanoma  13  Our 3rd approved I-O agent; Potential to be new SOC in 1L melanoma  Clinically meaningful efficacy  Continued U.S. revenue growth driven by strong demand  Broad Expansion Opportunities  Share in 1L melanoma: mid-to-upper teens  Continued growth opportunity: PD-1 monotherapy maintains ~20% share  1As of Q3 2022; Source: BMS Market Research, Brand Impact W.E.   NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approvalFinancial projections may contain non promoted sales, BMS promotes only according to label  Global Net Sales $M  P1  P2  P3  Adjuvant Melanoma  HCC  1L  2L+  MSS CRC  2L  1L  NSCLC  Key Metrics1  $4B+ 2030 NRA sales potential  Camzyos  Sotyktu  Opdualag 
 
 Camzyos nHCM  Sotyktu SLE  Opdualag 1L NSCLC  Breyanzi 3L+ CLL  Breyanzi 3L+ iNHL  Reblozyl MF  Planned Next 1-2 Years  Sotyktu PsA  Zeposia CD  Milestones Already Delivered that De-Risk 2025–2030 and Beyond  Zeposia MS  Reblozyl 2L TD MDS  Breyanzi 3L+ LBCL  Abecma 5L+  Zeposia UC  Camzyos oHCM  Sotyktu PsO  Opdualag 1L Mel FDC  Breyanzi 2L LBCL  Abecma 3-5L  Reblozyl 1L MDS  Onureg AML maint.  New Product Portfolio Significantly De-Risked with Important Catalysts Ahead  14  *Non-risk adjusted revenue potential, subject to positive registrational trials and health authority approval  **Other includes: Abecma, Onureg, Inrebic, and Opdualag  Financial projections may contain non promoted sales, BMS promotes only according to label  Camzyos  Reblozyl  Breyanzi  Zeposia  Sotyktu  Other**  2025  $10B - $13BRisk-Adjusted Sales  $25B+ Non-Risk Adjusted*  2030  $4B+  $4B+  $4B+  $4B+  $3B+  $3B+  $1B+  Key Milestones  Beyond  Opdualag Adj. Mel  Opdualag 2L+ MSS CRC 
 
 Well Positioned for Portfolio Renewal & Long-Term Growth  15  1. Portfolio renewal well-underway: 9 new launches  2. Next wave of innovation: 6 registrational stage pipeline assets  3. Optionality from early-stage pipeline & BD 
 
 Exciting Registrational Stage Portfolio with 6 Differentiated Assets — Further Supports Growth Opportunity in 2H of Decade  16  Next generation anti-thrombotic  Ph3 program initiating in 2023 in SSP, Afib, & ACS  milvexian  Planned launch in ROS1+ NSCLC  Potential best-in-class ROS1/NTRK inhibitor  repotrectinib  Potential first-in-class oral LPA1 antagonist  BMS-986278  Ph3 initiation planned in lung fibrosis in 2023  Potentially differentiated anti IL-13  cendakimab  Ph3 underway in eosinophilic esophagitis  Potential first-in-class CELMoD agent  iberdomide  2L+ Ph3 initiated & post-transplant maintenance trial   planned for 2023 in multiple myeloma  Highly potent CELMoD agent  Ph3 initiated in relapsed/refractory multiple myeloma  mezigdomide  Late-stage pipeline: $10B+ peak non-risk-adjusted revenue potential  Non-Risk Adjusted sales subject to positive registrational trials and health authority approval 
 
 LPA1  cendakimab  repotrectinib  CELMoDs  Milvexian: Next-Generation Antithrombotic with $5B+ NRA Potential1 With Positive POC Data Supporting Phase 3 Initiation  17  Differentiated Monotherapy Profile  AXIOMATIC-TKR Phase 2 data (NEJM 2021)  Clear efficacy vs. enoxaparin  Differentiated safety profile vs. FXa inhibitors  No dose response in bleeding observed in doses ≥50 mg  AXIOMATIC-SSP Phase 2 data (ESC 2022)  Compelling reduction in symptomatic ischemic strokes  No signal for increase in intracranial bleeds (BARC 3c)  No fatal bleeding (BARC 5)  Differentiated Profile in Combination  1Represents potential molecule sales; economics shared with JNJ; 2Ph3 studies are conducted by Janssen  BARC: Bleeding Academic Research Consortium; BARC Type 3c = Intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision; BARC Type 5 = Probable fatal bleeding or definite fatal bleeding (overt or autopsy or imaging confirmation)  NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval; Financial projections may contain non promoted sales, BMS promotes only according to label  Dose  Enrollments  Key criteria  Comparator  Primary endpoint  Start date  25 mg BID  ~15,000  Acute ischemic stroke or high-risk TIA  Placebo (background antiplatelet therapy)  Time to first occurrence of ischemic stroke  Jan./Feb. 2023  Initial Study: Secondary Stroke Prevention (SSP)  Registrational program2 focused on 3 core indications: SSP, ACS, AF  Atrial Fibrillation & Acute Coronary Syndrome trials to initiate in 1H 2023  milvexian 
 
 Novel CELMoD Agents: Opportunity to Sustain a Leadership Position in Multiple Myeloma  18  Potency translating to strong response rates in a heavily pretreated 4L+ patient population, including IMiD-refractory & anti-BCMA-exposed  40% ORR; 50% ORR in patients with prior BCMA-targeted therapy2  Profile supports combination with PIs  LPA1  milvexian  cendakimab  Registrational trials underway  Encouraging response rates in a heavily pretreated 4L+ patient population  26% ORR1   Tolerability profile supports combination therapy in earlier lines  Iberdomide  Efficacious and tolerable agent; prioritized for use in earlier lines  Mezigdomide  Highly potent agent; prioritized for use in relapsed/refractory multiple myeloma  Potential to be New Backbone in Post-Transplant Maintenance & with anti-CD38 in RRMM  Potential to be New Backbone with Proteasome Inhibitors in RRMM  1Lancet Haematol 2022; 9: e822–32.  2Blood (2022) 140 (Supplement 1): 1366–1368.  BCMA; B-cell maturation antigen  IMiD; immunomodulatory agents  repotrectinib  CELMoDs 
 
 LPA1 Antagonist (BMS-986278): First-in-Class Novel Treatment for Lung Fibrosis  19  IPF is a fatal lung disease with median 3-5 years survival  In 2021, >700,000 adults living with IPF globally1  Worldwide sales2 of 2 approved agents $3B+  Significant Unmet Need and Market  Development Plans  LPA1 is central to the pathogenesis of fibrotic diseases  BMS-986278 demonstrates compelling efficacy and favorable safety profile  BMS-986278  LPA production is stimulated by lung injury  LPA activates LPA1 expressed on fibroblasts   Excessive collagen secreted by fibroblasts leads to fibrosis  Lung Injury  ALVEOLUS  1DataMonitor, IPF Pharma Intelligence Market Spotlight, Feb-2022  2Source: Evaluate Pharma; 2021 WW Esbriet & Ofev sales (USD)  LPA1; lysophosphatidic acid receptor 1  IPF; idiopathic pulmonary fibrosis   PPF; progressive pulmonary fibrosis  Phase 2 IPF positive data in house (2H 2022) & PPF cohort ongoing  Planning to initiate Phase 3 program in 2023  milvexian  cendakimab  repotrectinib  CELMoDs  LPA1 
 
 LPA1  Clinically differentiated profile in NSCLC  Repotrectinib: Potential Best-in-Class ROS1 Inhibitor in NSCLC  20  ROS1 Prevalence:~1.5% of NSCLC patients2  Existing ROS1 market:~$500-$600M3  Opportunity to roughly double the ROS1 market & achieve best-in-class share based on:  Longer duration of response  Higher response rate  Better safety / tolerability profile  ROS1+ TKI-Naïve NSCLC; ORR (95% CI)  79%  TKI-Pretreated Activity  ORRs of 28-42% (n=100)  CNS Activity (ROS1+ NSCLC)    ROS1+ TKI-NaïveNSCLC Durability  DOR  12-month DOR1: 86.1%  mDOR: not yet reached  PFS  12-month PFS1: 79.7%  mPFS: not yet reached  Generally Well Tolerated Safety Profile  Favorable Safety Profile  Source: Chul Cho B, et al. ENA 2022  Market Potential  Highly Potent & Differentiated Small Molecule  1Based on Landmark analysis  2Source: Decision Resources Group; BMS Internal Analysis; AJCC 8th Edition Staging, ROS1 based on external analysts and IQVIA  3WW total revenue for crizotinib and entrectinib in 2021  milvexian  cendakimab  CELMoDs  repotrectinib 
 
 EoE is a life altering disease affecting ~700k1 prevalent patients (combined U.S./EU5)  Potentially differentiated MoA addressing a significant unmet need for a highly efficacious treatment that improves both inflammation & fibrosis/remodeling  Cendakimab: High-Affinity IL-13 Neutralizing Antibody for EoE  21  Co-primary (week 24):  Change in dysphagia days  Histologic response: eos ≤6/hpf  Key secondary (weeks 24 & 48):  Histologic response: eos <15/hpf  EREFS  EoE-HSS  mDSD composite score  EoE: Currently Enrolling Phase 3 study  eos; eosinophils  EREFS; endoscopic reference score  Week 24  Co-Primary Endpoints   Week 48   Secondary Endpoints   Cendakimab 360 mg SC Q2W  Placebo  Cendakimab 360 mg SC QW  Cendakimab 360 mg SC QW  Induction Phase  24 weeks  Maintenance Phase  24 weeks  Binds to IL-13 ligand  Blocks IL-13 binding to both IL-13Ra1 & IL-13Ra2 subunits  Eosinophilic Esophagitis + Cendakimab  Fibrosis and Remodeling  Tissue   Inflammation  Readout anticipated in 2024  EoE-HSS; Eosinophilic Esophagitis Histology Scoring System  mDSD; modified daily symptom diary   milvexian  repotrectinib  CELMoDs  LPA1  cendakimab  1Source: Decision Resources Group; BMS Internal Analysis 
 
 Well Positioned for Portfolio Renewal & Long-Term Growth  22  1. Portfolio renewal well-underway: 9 new launches  2. Next wave of innovation: 6 registrational stage pipeline assets  3. Optionality from early-stage pipeline & BD 
 
 Robust Early-Stage Pipeline Provides Potential for Future Growth  23  50+ Assets inPhase 1/2*  Results Expected Next 18-24 Months  InnovationEngine  Small Molecule | Complex Biotherapeutics | Protein Homeostasis | Cell Therapy  Leading Drug Discovery Platforms  Solid Tumors 24  Hematology 12  Immunology & Fibrosis 10  Cardiovascular 4  Neuroscience 4  Deep internal pipeline  External collaborations and partnerships  >15 potential decisionsto advance to late-stagedevelopment  Continued Pipeline Replenishment with 30+ IND Planned from 2023 - 2025  *Source: BMS Pipeline as of Q3 2022 
 
 3 Near-Term Opportunities to Potentially Transition to Registrational Development  24  CELMoD targeting lymphoma with optionality to combine with SOC & novel agents   Opportunity to move into earlier lines  POC data expected in 2023 to inform Ph3  CC-99282  Potentially differentiated BCMA bispecific with a unique 2+1 construct  Low rates of CRS with SubQ formulation  Ph3 initiation planned in 2023/2024  alnuctamabBCMA TCE  AR-LDD  Small molecule targeting prostate cancer  POC underway including dose optimization  Opportunity to expand protein homeostasis in solid tumors 
 
 2023 Key Milestones  Opdivo (+/- Yervoy)  Early Stage:  Neo-adjuvant NSCLC Ph3 (CM-816) approval in EU  Metastatic  1L mCRPC Ph3 (CM-7DX)  Opdualag  1L NSCLC Ph2  repotrectinib  ROS1+ NSCLC (TRIDENT-1) U.S. filing  Abecma  3-5L MM Ph3 (KarMMa-3) filing  Initiation NDMM Ph3 (KarMMa-9)  Breyanzi  2L TE LBCL EU approval  3L+ CLL Ph2 (TRANSCEND-CLL)  3L+ FL Ph2 (TRANSCEND-FL)  Continued Near-term Catalysts Across Diversified Portfolio  25  Milestones represent data read-outs unless otherwise specified  To be expanded to include regulatory milestones pending future registrational successes  iberdomide  Initiation of pivotal post-transplant maintenance H2H vs Revlimid  Reblozyl  1L MDS (COMMANDS) U.S. filing  Sotyktu  Mod-to-severe PsO EU approval  CD Ph2 (IM011-023)  UC Ph2 (IM011-127)  LPA1 Antagonist  Initiation IPF Ph3  PPF Ph2 (IM011-040)  Camzyos  oHCM EU approval  milvexian  Initiation Ph3 program1  2024/2025 Key Milestones  Opdivo (+/- Yervoy)  Metastatic:  1L HCC Ph3 (CM-9DW)  1L+ MSI High CRC Ph3 (CM-8HW)  Early Stage:  Peri-adj NSCLC Ph3 (CM-77T)  Peri-adj MIBC Ph3 (CM-078)  Adj HCC Ph3 (CM-9DX)  Stage III Unresectable NSCLC Ph3 (CM-73L)  Adj NSCLC Ph3 (ANVIL, co-op group)  Opdualag  1L HCC Ph2  2L HCC Ph2  2L+ MSS mCRC Ph3  alnuctamab  BCMA TCE  Initiation MM Ph3  Reblozyl  1L MF Ph3 (INDEPENDENCE)  cendakimab  EoE Ph3  Sotyktu  PsA Ph3  Zeposia  CD maintenance Ph3 (YELLOWSTONE)  1SSP, ACS, AF Trials conducted by Janssen 
 
 Strong Cash Flow & Financial Flexibility Enables Balanced Approach to Capital Allocation  26  *Future dividend payouts subject to board authorization  1 As of Q3’22  Prioritizing Business Development  Strengthening theBalance Sheet  Returning Cash to Shareholders  Continue to focus on bolt-on opportunities to further strengthen long-term outlook  Replenish and diversify portfolio  ~$5B debt paid in 2022   Maintain strong investment-grade credit rating  Continued annual dividend growth*   14th consecutive dividend increase announced Dec ’22  Capital Allocation  Flexibility for continued opportunistic share repurchase - $9.5B remaining authorization1  
 
 Business Development: Converting Balance Sheet Strength to Revenue Growth  27  7 new product approvals  30+ clinical pipeline assets2  2 new research platforms (Protein Homeostasis, Cell Therapy)  of expected revenue in 2030  Company Strengths  Transaction Benefits Achieved1  Supporting 2H of Decade  Strengthened Innovation Engine  Supports Profitability  Key Transactions  ~100 early-stage deals   2019  2020  2022  Scientific expertise  Financial discipline  Successful integrations  2019 - 2022  $3B+ synergies  NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval  Financial projections may contain non promoted sales, BMS promotes only according to label  1Includes acquisitions of Celgene, MyoKardia, Turning Point Therapeutics, & early-stage deals  2Source: BMS Pipeline as of Q3 2022  ~50% 
 
 Well Positioned for Portfolio Renewal & Long-Term Growth  28  Positioned for waves of innovation  Increasingly younger and more diversified portfolio  Strong scientific expertise across key therapeutic areas  Expanded registrational stage pipeline of 6 assets  Significant optionality from 50+ assets in early pipeline  3 approved first-in-class products in 2022  Strong commercial momentum  Long-term potential increasingly de-risked  Strong cash flows  Consistent, balanced approach to capital allocation  Financial flexibility to support additional business development  Strong Execution  TransformativeNew Product Portfolio  Deep Pipeline  Continued Financial Strength 
 
 
 Year-Ended December 31  2020  2021  2021  Total Revenues  $42,518  $46,385  Gross Profit  $30,745  $36,445  Specified items (a)  $3,300  $603  Gross Profit excluding specified items  $34,045  $37,048  Marketing, selling and administrative  $7,661  $7,690  Specified items (a)  ($279)  ($3)  Marketing, selling and administrative excluding specified items  $7,382  $7,687  Gross Profit  $10,048  $10,195  Specified items (a)  ($903)  ($843)  Gross Profit excluding specified items  $9,145  $9,352  Operating margin  31%  40%  Specified items (a)  10%  3%  Operating margin excluding specified items  41%  43%  Bristol Myers Squibb Company Reconciliation of Certain GAAP Line Items to Certain Non-GAAP Line Items  30  (a): An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable GAAP financial measure are available on our website at bms.com/investors. Operating margin on Specified Items represents the difference between the GAAP and Non-GAAP operating margin  (Unaudited, dollars in millions) 
 
 Phase I  Clinical Development Portfolio – Phase I and II   NME leading indication  Hematology  Neuroscience  Oncology  Fibrosis  Immunology  CV  COVID-19  ^ Trials exploring various combinations  1. BMS has an exclusive option to license and/or option to acquire  ª Anti-CTLA-4 NF  Solid Tumors  ª Anti-CTLA-4 Probody  Solid Tumors  ª Anti-Fucosyl GM1^  Solid Tumors  ª Anti-IL-8^  Solid Tumors  ª Anti-TIGIT^  Solid Tumors  ª BET Inhibitor (CC-90010)^  Solid Tumors  ª farletuzumab ecteribulin  Solid Tumors  ªrepotrectinib  ROS1 NSCLC  NTRK NSCLC  OPDIVO  Colorectal Cancer 2L  Pan-Tumor TMB High  Solid Tumors  OPDIVO+YERVOY  Metastatic Castration-Resistant Prostate Cancer 2L  Solid Tumors   OPDIVO+CDK4/6 Inhibitor  Neoadjuvant ER+/HER2- Breast Cancer  nivolumab+relatlimab  Stage IV Non-Small Cell Lung Cancer 1L   Hepatocellular carcinoma 1L  Hepatocellular carcinoma 2L  ª A/I CELMoD (CC-99282)^  RR Non-Hodgkin’s Lymphoma  ª BET Inhibitor (BMS-986158)  Hematologic Malignancies   mezigdomide (CC-92480)  Multiple Myeloma 4L+   Multiple Myeloma 2L+ & Newly Diagnosed Multiple Myeloma   ABECMA (ide-cel)  Newly Diagnosed Multiple Myeloma, 2L, 4L+  BREYANZI (liso-cel)  Chronic Lymphocytic Leukemia (CLL) 3L+  Follicular Lymphoma (FL) 3L+  Marginal Zone Lymphoma (MZL) 3L+  Mantle Cell Lymphoma (MCL) 3L+  IDHIFA  Acute Myeloid Leukemia 1L  iberdomide  Multiple Myeloma 4L+ & Newly Diagnosed Multiple Myeloma   OPDIVO+EMPLICITI  RR Multiple Myeloma  ªCardiac Myosin Inhibitor   (MYK-224)  Obstructive Hypertrophic Cardiomyopathy  ª danicamtiv  Genetic Dilated Cardiomyopathy  ª milvexian (FXIa Inhibitor)  Venous Thromboembolism (VTE) Prevention  Secondary Stroke Prevention  CAMZYOS  Heart Failure with preserved Ejection Fraction (HFpEF)  ª afimetoran (TLR 7/8 Inhibitor)  Systemic Lupus Erythematosus  ª branebrutinib  Rheumatoid Arthritis  ª MK2 Inhibitor  Ankylosing Spondylitis  cendakimab  Atopic Dermatitis  SOTYKTU  Crohn’s Disease  Discoid Lupus Erythematosus  Systemic Lupus Erythematosus  Ulcerative Colitis  ª HSP47  Non-alcoholic Steatohepatitis (NASH)  ª LPA1 Antagonist  Pulmonary Fibrosis  ORENCIA  COVID-19 Treatment  Phase II  Phase II  31  ª AHR Antagonist 1^  Solid Tumors  ª Anti-CCR8^  Solid Tumors  ª Anti-CTLA-4 NF Probody^  Solid Tumors  ª Anti-ILT4^  Solid Tumors  ª Anti-NKG2A^  Solid Tumors  ª Anti-SIRPα  Solid Tumors  ª AR-LDD  Solid Tumors  ª CD3xPSCA Bispecific1   Solid Tumors  ª DGK Inhibitor  Solid Tumors  ª IL-12 Fc^  Solid Tumors  ª JNK Inhibitor  Advanced Solid Tumors  ª LSD1 Inhibitor^  Solid Tumors  ª MAGE A4/8 TCER  Solid Tumors  ª SHP2 Inhibitor^  Solid Tumors  ª STING Agonist^  Solid Tumors  ª TGFβ Inhibitor^  Solid Tumors  ª TIGIT Bispecific  Solid Tumors  OPDIVO  Solid Tumors  OPDIVO+YERVOY  Solid Tumors  ª alnuctamab BCMA TCE  RR Multiple Myeloma   ª Anti-SIRPα  Hematologic Malignancies  ª BCMA ADC^  RR Multiple Myeloma   ª BCMA NKE  RR Multiple Myeloma   ª BET Inhibitor (CC-90010)^  Hematologic Malignancies  ª CD33 NKE  RR Multiple Myeloma   ª CD47xCD20  Non-Hodgkin’s lymphoma  ª CK1α Degrader  Hematologic Malignancies  ª GPRC5D CAR T  RR Multiple Myeloma   ª GSPT1 CELMoD (CC-90009)^  RR Acute Myeloid Leukemia  ª ROR1 CAR T  Hematologic Malignancies  iberdomide^  Diffuse Large B-cell Lymphoma 1L  RR NHL, LBCL, FL 3L+   OPDIVO  Hematologic Malignancies  ª FXIa Inhibitor  Thrombotic Disorders  ª Anti-CD40  Autoimmune Disease  ª RIPK1 Inhibitor  Autoimmune Disease  ª IL2-CD25  Autoimmune Disease  ª TYK2 Inhibitor  Autoimmune Disease  afimetoran (TLR 7/8 Inhibitor)  Cutaneous Lupus Erythematosus  ª NME  Fibrosis  ª Anti-Tau  Neuroscience  ª BTK Inhibitor  Neuroscience  ª eIF2b Activator  Neuroscience  ª FAAH/MGLL Dual Inhibitor  Neuroscience  Data as of October 26th, 2022 
 
 32  Development Partnerships: ABECMA (ide-cel): 2seventy bio; AHR: Ikena Oncology; Anti-Tau: Prothena; CAMZYOS in China, Singapore, Thailand, Macau, HK, Taiwan: LianBio; CD3xPSCA: Avencell; eIF2b Activator: Evotec; TIGIT Bispecific: Agenus; ELIQUIS: Pfizer; EMPLICITI: AbbVie; farletuzumab ecteribulin: Eisai; HSP47: Nitto Denko Corporation; rHuPH20: Halozyme; ; IDHIFA: Servier; IL-12 Fc: Dragonfly Therapeutics; MAGEA4/8 TCR: Immatics; milvexian: Janssen Pharmaceuticals, Inc.; OPDIVO, YERVOY, OPDUALAG: Ono; REBLOZYL: Merck; SHP2 Inhibitor: BridgeBio Pharma   Registration US, EU, JP  Clinical Development Portfolio – Phase III   Phase III  ª subcutaneous nivolumab + rHuPH20  Adjuvant Melanoma  Renal Cell Carcinoma 2L  OPDIVO  Adjuvant Gastric Cancer  Adjuvant Melanoma  Adjuvant Hepatocellular Carcinoma  Metastatic Castration-Resistant Prostate Cancer 1L   Peri-adjuvant Muscle Invasive Urothelial Carcinoma  Peri-adjuvant Non-Small Cell Lung Cancer   OPDIVO + YERVOY  Adjuvant Renal Cell Carcinoma   Hepatocellular Carcinoma 1L  Bladder Cancer 1L  Microsatellite Instability High Colorectal Cancer 1L+   Stage 3 Unresectable Non-Small Cell Lung Cancer   OPDUALAG  Adjuvant Melanoma  Microsatellite Stable Metastatic Colorectal Cancer 2L+  ª iberdomide  Multiple Myeloma  2L+  ª mezigdomide (CC-92480)  Multiple Myeloma 2L+   ABECMA (ide-cel)  Multiple Myeloma  3L-5L  INREBIC  Myelofibrosis previously treated with Ruxolitinib  REBLOZYL  TD Myelodysplastic Syndrome Associated Anemia 1L  TD Myelofibrosis Associated Anemia 1L   CAMZYOS  Non-Obstructive Hypertrophic Cardiomyopathy  ª cendakimab  Eosinophilic Esophagitis  SOTYKTU  Psoriatic Arthritis  ZEPOSIA  Crohn’s Disease  SOTYKTU  Moderate to Severe Psoriasis (EU)  OPDIVO  Neoadjuvant Non-Small Cell Lung Cancer (EU, JP)  BREYANZI  Large B-cell Lymphoma 2L TE (EU)  Large B-cell Lymphoma 2L TE & TNE (JP)  REBLOZYL  B-Thalassemia NTD (EU)  CAMZYOS  Obstructive Hypertrophic Cardiomyopathy (EU)  Obstructive Hypertrophic Cardiomyopathy SRT eligible (US)  NME leading indication  Hematology  Neuroscience  Oncology  Fibrosis  Immunology  CV  COVID-19  Data as of October 26th, 2022 
 
 Our Commitment as a Purpose Driven Organization  33  Embracing environmental stewardship  Experienced & diverse Board   Board oversight of strategy& key enterprise risks  64% female & ethnically diverse directors  Shareholder rights  Regular shareholder engagement  Proxy access   Special meeting right (15%)  Environment  Governance  Social  Key Priorities  Our Commitments  2021  ≥ 25% new clinical trial sites in diverse metro areas  2022  Gender parity at executive level  2X representation for Black/African American & Hispanic/Latino executives  2025  $1B spend with diverse suppliers  2024  Set scientifically validated goals to reduce our emissions  2030  100% renewable electricity  2040  Net neutral GHG  100% EV fleet  100% equitable water use  Zero waste to landfill  Maintaining highest ethics, integrity & compliance  Upholding Board oversight & accountability  Promoting product quality & safety  Cultivating diversity, equity & inclusion  Ensuring health equity, patient access & innovation 
 
 Strong Cash Flow & Financial Flexibility Enables Balanced Approach to Capital Allocation  25  *Future dividend payouts subject to board authorization  1 As of Q3’22  Prioritizing Business Development  Strengthening theBalance Sheet  Returning Cash to Shareholders  Continue to focus on bolt-on opportunities to further strengthen long-term outlook  Replenish and diversify portfolio  ~$5B debt paid in 2022   Maintain strong investment-grade credit rating  Continued annual dividend growth*   14th consecutive dividend increase announced Dec ’22  Capital Allocation  Flexibility for continued opportunistic share repurchase - $9.5B remaining authorization1